Celltrion Wins French Tender for Remsima, Herzuma, and Vegzelma

Celltrion announced on June 20th the successful acquisition of significant contracts for its autoimmune disease treatments, including Remsima, Herzuma, and Vegzelma. These agreements were secured through a tender by UniHA, a leading French pharmaceutical procurement organization comprising major university hospitals.

UniHA is a critical player in the French healthcare industry, holding substantial market shares: approximately 30% in the infliximab market, 27% in the bevacizumab market, and 13% in the trastuzumab market. Under this tender, Celltrion will exclusively supply these three products from this month until 2027.

Additionally, Celltrion has secured contracts for Herzuma and Vegzelma through a tender by Bretagne, a union of public hospitals in France. These contracts will extend for four years, beginning this month until 2028

Celltrion's focused strategy on building strong relationships with tender officials has led to significant market achievements. According to IQVIA, in the fourth quarter of last year, Remsima achieved a 50% market share, Truxima held a 26% share, and the subcutaneous formulation Remsima SC captured 26%. Collectively, the Remsima product line achieved a 76% market share, solidifying its position as the leading treatment in the French infliximab market.

Looking ahead, Celltrion plans to enhance its participation in the French tender market, aiming to sustain its growth trajectory. The company will also bolster its sales competitiveness with upcoming products, including Omlyclo (omalizumab), a biosimilar to Xolair, which recently received marketing authorization from the European Medicines Agency (EMA), and the Stelara biosimilar CT-P43.